Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

Annemarie Lekkerkerker - Scientist, OMNI Biomarker Development

Annemarie Lekkerkerker

Scientist, OMNI Biomarker Development

"I am excited to be part of the Genentech family where we are driving the drug development process through cutting-edge research, deepening our understanding of disease pathogenesis and translating this into clinical biomarker strategies."
Years at Genentech

I joined Genentech in the spring of 2014 as Scientist in the OMNI Biomarker Development group. Prior to joining Genentech, I worked in academic research and as director in a biotech startup active in target discovery in inflammatory, autoimmune and fibrotic diseases. In my current role, I am responsible for specific clinical biomarker strategies, in support of the development of medicines in inflammatory and autoimmune diseases both in small and large molecule programs. I am passionate about biomarkers and strongly believe they will deepen our understanding of the activity of molecular targets and disease pathogenesis, enabling decision-making in drug development.

I am also the biomarker lead in the inflammatory bowel disease franchise leading a team that outlines the overarching IBD biomarker strategy, focusing on preclinical and clinical biomarker discovery efforts across different disciplines. I enjoy working in cross-functional teams, which is central to my everyday job at Genentech and integral to successful drug development.

Featured Publication

Cellular players in lung fibrosis.

Curr Pharm Des. 2012;18(27):4093-102.

Lekkerkerker AN, Aarbiou J, van Es T, Janssen RA.